Knowing the homologous recombination deficiency (HRD) status of advanced ovarian cancer patients can provide key prognostic information and guide important treatment decisions. That’s why this five-part series features a panel of experts who discuss the practical aspects of genomic testing in advanced ovarian cancer care, including its purpose, how to successfully implement testing in clinical practice, and how to communicate the value of HRD testing to patients. The panel includes Drs John Nakayama, Alexander Olawaiye, and Joshua Kesterson.
©2023 AstraZeneca. All rights reserved. US-81081 Last Updated 11/23